A prospective, randomized, parallel group, double blind, multicenter study to compare the efficacy, safety and immunogenicity of Lupin's Ranibizumab with Lucentis ® in patients with neovascular age-related macular degeneration - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35918962/
1 Professor, Department of Ophthalmology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India. 2 Vitreo Retinal Surgeon-Department of Ophthalmology, Rising Retina Clinic, Ahmedabad, Gujarat, India. 3 Consultant, Department of Ophthalmology, Kanoria Hospital and Research Center, Gandhinagar, Gujarat, India. 4 Consultant, Department of Ophthalmology, Dhadiwal Hospital, Nashik, Maharashtra, India.
Conclusion: Lupin’s biosimilar ranibizumab demonstrated therapeutic equivalence, desirable safety, and favorable immunogenicity profile compared to Lucentis®.